MHC
REGN icon

Meyer Handelman Company’s Regeneron Pharmaceuticals REGN Stock Holding History

Meyer Handelman Company’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.99M Sell
2,581
-297
-10% -$227K 0.06% 127
2025
Q4 		$2.22M Buy
2,878
+18
+0.6% +$12.2K 0.07% 127
2025
Q3 		$1.61M Sell
2,860
-612
-18% -$346K 0.05% 143
2025
Q2 		$1.82M Sell
3,472
-522
-13% -$291K 0.06% 136
2025
Q1 		$2.53M Sell
3,994
-125
-3% -$86K 0.09% 125
2024
Q4 		$2.93M Sell
4,119
-141
-3% -$118K 0.1% 118
2024
Q3 		$4.48M Sell
4,260
-5
-0.1% -$5.56K 0.15% 107
2024
Q2 		$4.48M Hold
4,265
– – 0.16% 102
2024
Q1 		$4.11M Hold
4,265
– – 0.14% 110
2023
Q4 		$3.75M Buy
4,265
+30
+0.7% +$24.7K 0.15% 110
2023
Q3 		$3.49M Buy
4,235
+435
+11% +$342K 0.14% 114
2023
Q2 		$2.73M Buy
3,800
+225
+6% +$173K 0.11% 124
2023
Q1 		$2.94M Buy
3,575
+70
+2% +$52.8K 0.12% 118
2022
Q4 		$2.53M Sell
3,505
-150
-4% -$111K 0.11% 122
2022
Q3 		$2.52M Buy
3,655
+50
+1% +$31.5K 0.12% 121
2022
Q2 		$2.13M Hold
3,605
– – 0.09% 124
2022
Q1 		$2.52M Buy
3,605
+460
+15% +$291K 0.1% 125
2021
Q4 		$1.99M Buy
3,145
+175
+6% +$108K 0.07% 128
2021
Q3 		$1.8M Hold
2,970
– – 0.07% 127
2021
Q2 		$1.66M Buy
2,970
+725
+32% +$367K 0.07% 134
2021
Q1 		$1.06M Buy
+2,245
New +$1.09M 0.04% 146

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Meyer Handelman Company's REGN Position: Q1 2026 in Review

Meyer Handelman Company reduced its Regeneron Pharmaceuticals (REGN) stake by 10% in Q1 2026, selling an estimated $227K and leaving 2,581 shares worth $1.99M. The position accounts for 0.06% of the portfolio, ranked #127.

Meyer Handelman Company first reported a position in REGN in Q1 2021 and has held it in 21 quarters since. The position peaked at $4.48M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Meyer Handelman Company held 2,581 shares of Regeneron Pharmaceuticals worth $1.99M as of Q1 2026.
  • Meyer Handelman Company sold 297 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $227K.
  • Regeneron Pharmaceuticals made up 0.06% of Meyer Handelman Company's portfolio in Q1 2026, its #127 holding.
  • Meyer Handelman Company first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • Meyer Handelman Company's Regeneron Pharmaceuticals position peaked at $4.48M in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Meyer Handelman Company's 13F filing for Q1 2026, filed 20 Apr 2026.